Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Ipca Labs

    Jump to

    • Buy Ipca Labs; target of Rs 1820: Motilal Oswal

      Motilal Oswal is bullish on Ipca Labs recommended buy rating on the stock with a target price of Rs 1820 in its research report dated March 17, 2026.

    • Ipca Labs Consolidated September 2025 Net Sales at Rs 2,556.50 crore, up 8.56% Y-o-Y

    • Ipca Labs Standalone September 2025 Net Sales at Rs 1,930.32 crore, up 6.59% Y-o-Y

    • Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y

    • Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y

    • Ipca Labs Consolidated March 2025 Net Sales at Rs 2,246.69 crore, up 10.51% Y-o-Y

    • Ipca Labs Consolidated December 2024 Net Sales at Rs 2,245.37 crore, up 9.38% Y-o-Y

    • Ipca Labs Consolidated September 2024 Net Sales at Rs 2,354.90 crore, up 15.78% Y-o-Y

    • Ipca Labs Standalone September 2024 Net Sales at Rs 1,810.94 crore, up 8.92% Y-o-Y

    • IPCA Labs shares hit fresh 52-week high as Nomura upgrades target price on strong growth plans

      Nomura bumped up its price target on IPCA Labs to Rs 1,750, seeing a 20 percent upside from the previous close.

    • Ipca Labs Consolidated June 2024 Net Sales at Rs 2,092.63 crore, up 31.81% Y-o-Y

    • Ipca Labs Standalone June 2024 Net Sales at Rs 1,565.86 crore, up 5.18% Y-o-Y

    • Ipca Labs Consolidated March 2024 Net Sales at Rs 2,033.01 crore, up 34.49% Y-o-Y

    • Ipca Labs Standalone March 2024 Net Sales at Rs 1,510.62 crore, up 7.78% Y-o-Y

    • Ipca Labs Consolidated December 2023 Net Sales at Rs 2,052.86 crore, up 32.79% Y-o-Y

    • Ipca Labs Standalone December 2023 Net Sales at Rs 1,506.83 crore, up 5.17% Y-o-Y

    • IPCA Labs Q3 net profit up 67% at Rs 180 crore

      IPCA Laboratories Q3 earnings: Revenue came in at Rs 2,052.86 crore, up 32 percent from year-ago quarter

    • Ipca Labs Standalone September 2023 Net Sales at Rs 1,662.67 crore, up 11.97% Y-o-Y

    • IPCA Labs Q2 Results: Net profit flat year-on-year at Rs 145 crore

      IPCA Labs Q2 earnings: Revenue from operations came in at Rs 2,034 crore, up 27 percent from Rs 1,601 crore year-ago quarter, the company said.

    • IPCA Pithampur unit in minimally acceptable state of compliance by US FDA

      IPCA Labs will release its Q2 results on November 10

    • Mixed day for pharma; Ipca Labs soars 7%, Laurus Labs tanks 10%

      The pharma sector has had a stellar run this year, so far, which also gives investors more leeway to take partial profits home

    • Ipca Labs hits 52-week high as Ratlam unit's VAI classification positively surprises Street

      Ipca's Ratlam manufacturing unit was previously issued 11 observations by the US FDA, which had prompted expectations among analysts of the unit receiving an Official Action Indicated (OAI) status, the most severe classification.

    • Ipca Labs Consolidated June 2023 Net Sales at Rs 1,587.58 crore, up 0.12% Y-o-Y

    • Ipca Labs Standalone June 2023 Net Sales at Rs 1,488.71 crore, up 1.32% Y-o-Y

    • IPCA Labs Q1 results: Net profit rises 14% to Rs 163 crore

      IPCA Labs Q1 earnings: The pharma company had reported a net profit of Rs 143.06 crore in the year-ago period

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347